Details for Patent: 8,895,601
✉ Email this page to a colleague
Which drugs does patent 8,895,601 protect, and when does it expire?
Patent 8,895,601 protects BALVERSA and is included in one NDA.
This patent has eighty-seven patent family members in forty-four countries.
Summary for Patent: 8,895,601
| Title: | Pyrazolyl quinoxaline kinase inhibitors |
| Abstract: | The invention relates to new quinoxaline derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer. |
| Inventor(s): | Gordon Saxty, Christopher William Murray, Valerio Berdini, Gilbert Ebai Besong, Christopher Charles Frederick Hamlett, Christopher Norbert Johnson, Steven John Woodhead, David Charles Rees, Laurence Anne Mevellec, Patrick René Angibaud, Eddy Jean Edgard Freyne, Timothy Pietro Suren Perera, Ronaldus Arnodus Hendrika Joseph Gilissen, Berthold Wroblowski, Jean Fernand Armand Lacrampe, Alexandra Papanikos, Oliver Alexis Georges Querolle, Elisabeth Thérèse Jeanne Pasquier, Isabelle Noëlle Constance Pilatte, Pascal Ghislain André Bonnet, Werner Constant Johan Embrechts, Rhalid Akkari, Lieven Meerpoel |
| Assignee: | Astex Therapeutics Ltd |
| Application Number: | US13/643,741 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 8,895,601
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-001 | Apr 12, 2019 | RX | Yes | No | 8,895,601 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-002 | Apr 12, 2019 | RX | Yes | No | 8,895,601 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| Janssen Biotech | BALVERSA | erdafitinib | TABLET;ORAL | 212018-003 | Apr 12, 2019 | RX | Yes | Yes | 8,895,601 | ⤷ Start Trial | Y | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,895,601
| Foriegn Application Priority Data | ||
| Foreign Country | Foreign Patent Number | Foreign Patent Date |
| United Kingdom | 1007286.6 | Apr 30, 2010 |
| PCT Information | |||
| PCT Filed | April 28, 2011 | PCT Application Number: | PCT/GB2011/050851 |
| PCT Publication Date: | November 03, 2011 | PCT Publication Number: | WO2011/135376 |
International Family Members for US Patent 8,895,601
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2563775 | ⤷ Start Trial | 301318 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2563775 | ⤷ Start Trial | CA 2025 00006 | Denmark | ⤷ Start Trial |
| European Patent Office | 2563775 | ⤷ Start Trial | PA2025509 | Lithuania | ⤷ Start Trial |
| European Patent Office | 2563775 | ⤷ Start Trial | C20250009 | Finland | ⤷ Start Trial |
| European Patent Office | 2563775 | ⤷ Start Trial | CR 2025 00006 | Denmark | ⤷ Start Trial |
| European Patent Office | 2563775 | ⤷ Start Trial | 122025000006 | Germany | ⤷ Start Trial |
| European Patent Office | 2563775 | ⤷ Start Trial | LUC00379 | Luxembourg | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
